Ropes & Gray advised Kailera Therapeutics, Inc. and its investors on the establishment of the company, its $400 million Series A financing, and the worldwide (ex-China) licensing by the company of a portfolio of clinical-stage metabolic disease assets from Hengrui Pharmaceuticals, a leading Chinese pharmaceutical company. Atlas Venture, Bain Capital Life Sciences, and RTW Investments led the Series A financing, with participation from Lyra Capital.
Kailera is a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. The company is based in Waltham, Massachusetts, and San Diego, California.
The Ropes & Gray team was led by New York-based corporate partner Arthur Mok, San Francisco-based licensing partner Geoffrey Lin, Boston-based corporate counsel Ray Grant and Boston-based licensing associate Evan Tallmadge. The team also included Singapore-based regulatory partner Katherine Wang, Washington D.C.-based national security partner Ama Adams, Washington D.C.-based antitrust partner Jonathan Klarfeld, Boston-based tax partners Amanda Holt and David Saltzman, and Boston-based executive compensation & employee benefits partner Renata Ferrari.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
